{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:55:14Z","timestamp":1791903314081,"version":"4.3.4"},"reference-count":25,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Plasma cell dyscrasias (PCDs) exhibit familial aggregation, yet data quantifying this risk through active screening remain limited. Herein, we designed this study to identify and quantify the familial risk of PCDs by detailed family trees and screening all first- and second-degree relatives of affected patients. We approached 1084 consecutive patients with PCDs at a single center between 2017 and 2019, of whom 864 eligible index patients provided consent to first- and second-degree relative screening. Detailed pedigrees were created for all patients, and screening with serum protein electrophoresis, immunofixation, and free light chain assays was performed. Spouses were also screened as a control group. In total, 2481 family members were screened; median age was 63 years. At least 1 additional family member with a monoclonal gammopathy (MG) was detected in 98 (11.3%) of the 864 screened families. A positive history of PCD or other B-cell malignancy was present in 2.1% of the families. Notably, the screening process identified 41 new cases of MGs (4.7% yield per family). The incidence was 4.5% among siblings and second-degree relatives compared to 2.6% in the control group. In conclusion, this large prospective study confirms a familial predisposition to PCDs, revealing that &amp;gt;11% of the affected families have multiple members with MGs, corresponding to at least twice the risk of PCDs among members of affected families. These findings support the potential clinical value of active screening for relatives of patients with PCDs to facilitate early diagnosis, appropriate monitoring, and prompt intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020394","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:50:46Z","timestamp":1784634646000},"page":"6444-6451","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["A prospective study of familial predisposition to plasma cell dyscrasias"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-1229","authenticated-orcid":false,"given":"Maria","family":"Gavriatopoulou","sequence":"first","affiliation":[{"name":"1Department of Clinical Therapeutics, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7857-5427","authenticated-orcid":false,"given":"Angeliki","family":"Andrikopoulou","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalini","family":"Migkou","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kanellias","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Eleutherakis-Papaiakovou","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta-Aikaterini","family":"Kokkali","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Malandrakis","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine Ivy","family":"Liacos","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8695-0493","authenticated-orcid":false,"given":"Tina","family":"Bagratuni","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6926-0351","authenticated-orcid":false,"given":"Foteini","family":"Theodorakakou","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8971-269X","authenticated-orcid":false,"given":"Charalampos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-8900","authenticated-orcid":false,"given":"Despina","family":"Fotiou","sequence":"additional","affiliation":[{"name":"2Clinic and Laboratory of Pathophysiology, Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece"},{"name":"3Department of Medicine, Korea University, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"2026101310430624100_bib1","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"2026101310430624100_bib2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-021-00480-w","article-title":"Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies","volume":"11","author":"R\u00f6gnvaldsson","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026101310430624100_bib3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"2026101310430624100_bib4","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.ejca.2005.11.033","article-title":"Familial risks and temporal incidence trends of multiple myeloma","volume":"42","author":"Altieri","year":"2006","journal-title":"Eur J Cancer"},{"issue":"9","key":"2026101310430624100_bib5","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ijc.24514","article-title":"Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden","volume":"125","author":"Kristinsson","year":"2009","journal-title":"Int J Cancer"},{"issue":"1","key":"2026101310430624100_bib6","first-page":"63","article-title":"Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study","volume":"3","author":"Eriksson","year":"1992","journal-title":"Cancer Causes Control"},{"issue":"2","key":"2026101310430624100_bib7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1056\/NEJMoa0708704","article-title":"Familial myeloma","volume":"359","author":"Lynch","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"2026101310430624100_bib8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood-2008-12-191676","article-title":"Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden","volume":"114","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2026101310430624100_bib9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41375-019-0703-6","article-title":"Genetic predisposition for multiple myeloma","volume":"34","author":"Pertesi","year":"2020","journal-title":"Leukemia"},{"key":"2026101310430624100_bib10","doi-asserted-by":"crossref","first-page":"12050","DOI":"10.1038\/ncomms12050","article-title":"Genome-wide association study identifies multiple susceptibility loci for multiple myeloma","volume":"7","author":"Mitchell","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"2026101310430624100_bib11","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.1038\/s41467-024-50932-7","article-title":"Deciphering the genetics and mechanisms of predisposition to multiple myeloma","volume":"15","author":"Went","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"2026101310430624100_bib12","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1038\/s41467-018-04989-w","article-title":"Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma","volume":"9","author":"Went","year":"2018","journal-title":"Nat Commun"},{"issue":"7","key":"2026101310430624100_bib13","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"2026101310430624100_bib14","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026101310430624100_bib15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"2026101310430624100_bib16","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"2026101310430624100_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ajh.24557","article-title":"Waldenstr\u00f6m macroglobulinemia: 2017 update on diagnosis, risk stratification, and management","volume":"92","author":"Gertz","year":"2017","journal-title":"Am J Hematol"},{"issue":"6","key":"2026101310430624100_bib18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/ejh.13757","article-title":"Risk of multiple myeloma and other malignancies among first- and second-degree relatives of patients with multiple myeloma: a population-based study","volume":"108","author":"Langseth","year":"2022","journal-title":"Eur J Haematol"},{"issue":"10","key":"2026101310430624100_bib19","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/j.clml.2019.09.509","article-title":"The PROMISE study: a nationwide project for predicting the progression of developing myeloma in a high-risk screened population","volume":"19","author":"Cowan","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"2026101310430624100_bib20","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","article-title":"Daratumumab or active monitoring for high-risk smoldering multiple myeloma","volume":"392","author":"Dimopoulos","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"2026101310430624100_bib21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41408-025-01337-2","article-title":"Assessing the performance of the Iceland screens, treats, or prevents multiple myeloma (iStopMM) model in a multicultural Bronx cohort: implications for monoclonal gammopathy of undetermined significance risk stratification","volume":"15","author":"Gor","year":"2025","journal-title":"Blood Cancer J"},{"issue":"4","key":"2026101310430624100_bib22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.7326\/M23-2540","article-title":"Development of a multivariable model to predict the need for bone marrow sampling in persons with monoclonal gammopathy of undetermined significance: a cohort study nested in a clinical trial","volume":"177","author":"Eythorsson","year":"2024","journal-title":"Ann Intern Med"},{"issue":"2","key":"2026101310430624100_bib23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","article-title":"Prevalence of smoldering multiple myeloma based on nationwide screening","volume":"29","author":"Thorsteinsd\u00f3ttir","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"2026101310430624100_bib24","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"issue":"25","key":"2026101310430624100_bib25","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6444\/2590640\/blooda_adv-2026-020394-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6444\/2590640\/blooda_adv-2026-020394-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:43:17Z","timestamp":1791902597000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/19\/6444\/569774\/A-prospective-study-of-familial-predisposition-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":25,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020394","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,13]]},"published":{"date-parts":[[2026,9,24]]}}}